PLX108819

GSE97078: AG-221 as an effective and on-target therapy in IDH2 mutant AML

• Organsim mouse
• Type RNASEQ
• Target gene
• Project ARCHS4

Herein we developed a multigenic AML model with inducible expression of IDH2R140Q and constitutive expression of mutant DNMT3AR882H and NRASG12D. Using genetic de-induction and the first-in-class IDH2 inhibitor AG-221, we demonstrate that despite the presence of multiple oncogenic lesions, AML cells expressing mutant IDH2 depend on continued production of 2-HG to maintain their leukemic potential. Moreover, by comparing pharmacological inhibition and genetic depletion of IDH2R140Q we validate AG-221 as a highly on target inhibitor and identify key downstream pathways including GATA1 that are critical for disease maintenance. SOURCE: Lev Kats (lev.kats@petermac.org) - Kats Peter MacCallum Cancer Centre